Address
HBM BioVentures AG
25 Grabenstrasse
6340 Baar
Switzerland
Phone
Website
Recent investment activity
KANDO id: 2990
Corporate information
Registration country
Funding rounds
Investment activity status
Active investor
Selected investments
Displaying 1 - 25 of 29Company | Profile | Country | Date | Funding | ||
---|---|---|---|---|---|---|
Arena Pharmaceuticals Inc | N/A | |||||
Broncus Technologies Inc | Developer of interventional bronchoscopy devices for the treatment of chronic lung diseases. | Debt | ||||
ChemoCentryx Inc | N/A | |||||
Delenex Therapeutics AG | Series A | |||||
Ellipse Technologies Inc | Series C | |||||
ESBATech AG | Switzerland based Biomedical Research Unit of Alcon | Series B | ||||
Icagen Inc | Biopharmaceutical company developing small molecule therapeutics that target ion channels for treatment of a variety of diseases. | N/A | ||||
Kolltan Pharmaceuticals Inc | Oncology therapeutics company, develops monoclonal antibody drugs targeting receptor tyrosine kinases. | Series A | ||||
Mpex Pharmaceuticals Inc | N/A | |||||
Nereus Pharmaceuticals Inc | Series E | |||||
Nereus Pharmaceuticals Inc | Series D | |||||
Nereus Pharmaceuticals Inc | N/A | |||||
Pacira Pharmaceuticals Inc | Acute care specialty pharmaceutical company. | N/A | ||||
Panomics Inc | Develops novel cell-based assays and tools to enable multiplexed measurements of molecular events in a quantitative and scalable manner | N/A | ||||
Probiodrug | Biopharmaceutical company focused on the development of innovative small molecule drugs. | Venture | ||||
Probiodrug | Biopharmaceutical company focused on the development of innovative small molecule drugs. | Series B | ||||
PTC Therapeutics Inc | Biopharmaceutical company. | N/A | ||||
Renovis Inc | N/A | |||||
Rigel Pharmaceuticals Inc | N/A | |||||
Acusphere Inc | Pharmaceutical firm developing porous micro-particle delivery systems. | N/A | ||||
Agensys Inc | Series D | |||||
Cylene Pharmaceuticals Inc | Clinical stage private company developing small molecule drugs against newly validated cancer targets. | Series D | ||||
Cylene Pharmaceuticals Inc | Clinical stage private company developing small molecule drugs against newly validated cancer targets. | Series C | ||||
Devax Inc | Developer of a drug-eluting stent for the treatment of vascular bifurcations. | N/A | ||||
ESBATech AG | Switzerland based Biomedical Research Unit of Alcon | Series B Initial investment |
Pagination
Team
Employee | Position | |||
---|---|---|---|---|
Joachim Rudolf | [email protected] | |||
Andreas Wicki | [email protected] |